List of Excipients in Branded Drug DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULPHATE

Generic Drugs Containing DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULPHATE

Company	Ingredient	NDC	Excipient
Golden State Medical Supply Inc	dextromethorphan hydrobromide and quinidine sulphate	84677-067	CROSPOVIDONE
Golden State Medical Supply Inc	dextromethorphan hydrobromide and quinidine sulphate	84677-067	D&C RED NO. 28
Golden State Medical Supply Inc	dextromethorphan hydrobromide and quinidine sulphate	84677-067	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULPHATE?

# Of NDCs	Excipient
1	CROSPOVIDONE
1	D&C RED NO. 28
1	D&C YELLOW NO. 10

Dextromethorphan Hydrobromide and Quinidine Sulfate: Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Dextromethorphan hydrobromide and quinidine sulfate are commercialized in the United States as Nuedexta, a fixed-dose capsule containing 20 mg dextromethorphan hydrobromide monohydrate and 10 mg quinidine sulfate. The product is FDA-approved for pseudobulbar affect, or PBA, in patients with neurologic disease. Its formulation challenge is unusual: quinidine is present at a low dose primarily to inhibit CYP2D6 and increase systemic exposure to dextromethorphan, not to provide the principal therapeutic effect. This makes excipient selection, dissolution control, content uniformity, and pharmacokinetic equivalence central to generic and reformulation strategy.[1]

The strongest commercial opportunities are low-cost generic capsules, alternative oral dosage forms, excipient-reduced products, and formulations designed for patients with swallowing difficulty. A successful product must preserve the dextromethorphan-quinidine exposure relationship while avoiding dissolution or absorption changes caused by excipient substitution.

What is the approved formulation of dextromethorphan and quinidine?

Nuedexta is an immediate-release, fixed-dose oral capsule. Each capsule contains:

Component	Amount per capsule	Functional role
Dextromethorphan hydrobromide monohydrate	Equivalent to 20 mg dextromethorphan hydrobromide	Active therapeutic ingredient
Quinidine sulfate	Equivalent to 10 mg quinidine sulfate	CYP2D6 inhibitor and pharmacokinetic enhancer
Microcrystalline cellulose	Not publicly quantified in the prescribing information	Diluent and compression or fill aid
Croscarmellose sodium	Not publicly quantified	Superdisintegrant
Colloidal silicon dioxide	Not publicly quantified	Glidant and flow aid
Magnesium stearate	Not publicly quantified	Lubricant
Capsule shell materials	Not publicly quantified	Gelatin-based shell, colorants and opacifier

The FDA label identifies the product as a capsule intended for oral administration once daily for seven days, followed by twice-daily dosing.[1] The product is not an extended-release dosage form. Its clinical differentiation comes from the pharmacokinetic interaction between the two active ingredients.

Why the active-ingredient ratio matters

Dextromethorphan undergoes extensive CYP2D6 metabolism. Quinidine inhibits this pathway, increasing dextromethorphan plasma exposure. A generic formulation therefore cannot be evaluated solely on the dissolution or bioavailability of dextromethorphan. It must maintain the relative exposure and tolerability profile of both active ingredients.

Quinidine also introduces cardiac and drug-interaction considerations. The FDA label warns about QT prolongation, torsades de pointes risk, contraindicated concomitant medicines, and CYP2D6-related interactions.[1] Excipients that materially alter absorption, gastric residence time, or dissolution could affect the pharmacokinetic exposure relevant to safety.

What excipients are most important for a generic formulation?

The key excipient functions are rapid disintegration, consistent wetting, low-dose content uniformity, and stable capsule filling. The product contains a relatively small total drug load, particularly for quinidine. That creates a potential segregation risk during blending and encapsulation.

Microcrystalline cellulose

Microcrystalline cellulose can provide bulk, improve powder handling, and support content uniformity. Grade selection affects:

• Bulk density
• Flowability
• Moisture sorption
• Blend segregation
• Capsule fill weight
• Disintegration behavior

A high-density grade may improve capsule-filling consistency but can produce a different dissolution profile from the reference product. A lower-density grade may improve disintegration while increasing fill-volume requirements.

Croscarmellose sodium

Croscarmellose sodium is a logical superdisintegrant for an immediate-release capsule. Its performance depends on particle size, degree of substitution, use level, and distribution through the blend. Excessive levels can increase swelling and produce variable wetting, while inadequate levels can slow rupture and dissolution.

For a generic product, croscarmellose sodium is more commercially defensible as a controlled-performance excipient than as a novel ingredient. The objective is to match the reference product’s dissolution behavior rather than maximize disintegration speed.

Colloidal silicon dioxide

Colloidal silicon dioxide improves powder flow and reduces adhesion to manufacturing equipment. It can also influence moisture behavior and blend uniformity. Excessive levels may alter powder density and capsule filling. The excipient is particularly relevant because the product requires reliable distribution of a low-dose quinidine component.

Magnesium stearate

Magnesium stearate is necessary for lubrication but can slow wetting and dissolution if overmixed or used at excessive concentrations. Lubrication time should be tightly controlled. A generic manufacturer seeking rapid dissolution should evaluate magnesium stearate concentration, particle size, blending energy, and hold time.

Capsule shell

A hard gelatin capsule is commercially simple and familiar to regulators. However, shell composition can affect moisture transfer, brittleness, color matching, and patient acceptability. Hypromellose capsules could support a vegetarian or moisture-sensitive positioning, but the substitution would require comparative stability and dissolution work.

Colorants and titanium dioxide can be removed or replaced in a new product to address consumer preferences, regional regulatory requirements, or excipient restrictions. Such changes should be assessed for visual differentiation, photostability, and bioequivalence impact.

How should a manufacturer design the excipient platform?

The preferred platform is a conventional immediate-release capsule with a low-risk excipient system. A practical development sequence is:

1. Establish a target product profile based on the reference capsule’s assay, dissolution, impurity profile, and stability.
2. Use a preblend or ordered blending process to distribute quinidine uniformly.
3. Screen microcrystalline cellulose grades for density and flow.
4. Compare croscarmellose sodium levels and grades for rapid capsule rupture.
5. Optimize colloidal silicon dioxide and magnesium stearate at the lowest effective levels.
6. Control lubrication time and blend hold time.
7. Compare gelatin and hypromellose shells only after the core formulation is stable.
8. Confirm dissolution across physiological pH conditions and discriminatory media.
9. Evaluate bioequivalence for both dextromethorphan and quinidine-related pharmacokinetic parameters.

A formulation with fewer excipients may have marketing value, but excipient reduction must not compromise blend uniformity or dissolution. Removing colloidal silicon dioxide or reducing lubricant levels can increase manufacturing variability. Removing a colorant may be commercially attractive but is unlikely to create meaningful intellectual-property protection by itself.

What formulation patents and regulatory protections matter?

The primary regulatory and intellectual-property issues are the fixed-dose combination, method of use for PBA, dosage regimen, and product-specific formulation claims.

Fixed-dose combination protection

The combination of dextromethorphan with quinidine is commercially important because quinidine changes the exposure profile of dextromethorphan. Claims directed to the combination, dose ratio, and use in neurologic conditions may be more relevant than conventional capsule-excipient claims.

Method-of-use protection

Nuedexta is approved for PBA associated with conditions including amyotrophic lateral sclerosis and multiple sclerosis. Method-of-use claims may address PBA treatment, dosing frequency, or clinical response. Such claims can complicate generic commercialization even when an abbreviated new drug application is otherwise approvable.

Formulation claims

Formulation claims may cover:

• The 20 mg/10 mg dose ratio
• Immediate-release delivery
• Specific release or dissolution characteristics
• Capsule composition
• Use of quinidine as a CYP2D6 inhibitor
• Stability and impurity control

Excipient-only claims are generally narrower and more vulnerable to design-around than claims directed to the active-ingredient combination or therapeutic use.

The FDA Orange Book remains the controlling source for currently listed patents and regulatory exclusivities.[2] Patent status must be assessed by product, patent, expiration date, listed claims, pediatric extension, and any litigation or settlement history. A patent that covers a method of use does not necessarily block all generic indications if the applicant uses a legally compliant label carve-out.

When does dextromethorphan-quinidine lose exclusivity?

The original Nuedexta approval occurred in 2010. The commercial exclusivity analysis is therefore no longer based on the initial new-drug exclusivity period. The current risks are patent expiry, paragraph IV litigation, labeling strategy, and the timing of ANDA approvals.

Exclusivity element	Commercial relevance
FDA approval	Nuedexta was approved in 2010 for PBA
New chemical entity exclusivity	Expired under the standard five-year framework
Orphan-drug exclusivity	The product was approved for PBA, but the applicable exclusivity period must be assessed against the original indication and approval date
Orange Book patents	Determine whether listed patents remain unexpired and enforceable
Pediatric exclusivity	Any six-month extension must be confirmed from FDA records
Method-of-use patents	May affect label content and launch strategy
ANDA approval	Can occur after statutory patent or exclusivity barriers are resolved
Commercial launch	May depend on litigation settlement, injunction, or at-risk launch decision

A precise generic-entry forecast requires matching each listed patent to its expiration date and litigation status. The most relevant business question is whether a generic applicant can obtain approval with a paragraph IV certification, a section viii carve-out, or a later approval date after patent expiry.

Which companies are challenging or competing with Nuedexta?

The competitive landscape has four segments:

1. Generic fixed-dose capsules. These are the closest substitutes and represent the largest direct price threat.
2. Dextromethorphan monotherapy. This approach generally produces lower and more variable exposure because it lacks quinidine-mediated CYP2D6 inhibition.
3. Alternative PBA treatments. No widely adopted FDA-approved pharmacologic alternative has achieved the same fixed-dose positioning for PBA.
4. Off-label or supportive treatments. Antidepressants and other neuropsychiatric medicines may be used off-label but do not replicate the approved dextromethorphan-quinidine formulation.

There is no biosimilar pathway for this product. Dextromethorphan and quinidine are small molecules, so competition proceeds through the ANDA pathway rather than the 351(k) biosimilar pathway.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue value through performance, supply assurance, and regulatory support rather than simple ingredient substitution.

High-value opportunities

Opportunity	Commercial rationale
Low-moisture microcrystalline cellulose	Supports capsule stability and consistent fill
Direct-flow excipient systems	Reduce segregation during low-dose quinidine blending
Rapid-disintegration platforms	Help match immediate-release dissolution
Hypromellose capsule shells	Support vegetarian and gelatin-free positioning
Low-peroxide excipients	Help manage oxidative degradation risk
Co-processed excipients	Improve flow and content uniformity
Global regulatory packages	Reduce qualification time for multinational manufacturers
Excipient supply redundancy	Lowers interruption risk for chronic-use products

A supplier with a strong drug-master-file package, compendial compliance, impurity data, and multi-site manufacturing can obtain a qualification advantage. The strongest value proposition is not a novel excipient claim. It is reproducible performance across commercial-scale batches.

What alternative dosage forms could expand the market?

The approved capsule is suitable for many patients but creates barriers for patients with dysphagia, advanced neurologic disease, or impaired dexterity.

Sprinkle capsule

A capsule that can be opened and sprinkled onto soft food could expand usability. The development burden includes:

• Stability after opening
• Uniform delivery of both active ingredients
• Powder adhesion and recovery
• Taste and bitterness
• Food-effect assessment
• Caregiver handling
• Labeling for administration

Because dextromethorphan and quinidine can have clinically important exposure and interaction effects, a sprinkle product should not be assumed to be therapeutically interchangeable with the capsule.

Orally disintegrating tablet

An orally disintegrating tablet could address swallowing difficulty and improve adherence. However, the bitter taste of dextromethorphan and quinidine creates a significant taste-masking problem. Ion-exchange resins, polymer coatings, lipid barriers, or multiparticulate systems could be required.

Oral suspension

A liquid product could serve patients unable to swallow capsules. The main technical barriers are taste, dose uniformity, chemical stability, preservative compatibility, and accurate delivery of the low quinidine dose. A suspension would also create a larger regulatory and manufacturing burden than a capsule.

Modified-release product

A modified-release product could reduce dosing frequency, but it would alter the pharmacokinetic profile that supports the existing regimen. This is a higher-risk development program and would likely require clinical bridging beyond routine generic bioequivalence.

What generic launch risks exist?

Generic manufacturers face five principal risks:

• Bioequivalence risk: Both active ingredients and their interaction must be characterized.
• Dissolution risk: Excipient substitutions may produce measurable differences in release.
• Label carve-out risk: Removing a patented method-of-use indication can create labeling and commercial constraints.
• Litigation risk: Paragraph IV certification may trigger patent litigation and a statutory stay of approval.
• Manufacturing risk: Low-dose quinidine distribution can create content-uniformity failures.

The lowest-risk path is a conventional immediate-release capsule with a close excipient architecture and a narrow manufacturing process window. A differentiated dosage form creates greater commercial upside but also increases clinical, regulatory, and intellectual-property exposure.

How strong is the patent estate for dextromethorphan-quinidine?

The strongest protection historically has come from the active-ingredient combination, dosing regimen, and PBA use rather than ordinary excipient selection. A new entrant should classify the estate into four categories:

Patent category	Risk to generic capsule	Design-around potential
Dextromethorphan-quinidine combination	High	Low to moderate
PBA method of use	Moderate to high	Moderate through label carve-out
Dose and regimen	Moderate	Moderate
Capsule excipient composition	Low to moderate	High
Alternative dosage form	Product-dependent	Moderate

The practical strength of the estate depends on claim construction, remaining term, Orange Book listing, prosecution history, and litigation outcomes. Patent expiration alone does not guarantee immediate commercial entry if regulatory exclusivity, litigation stays, or manufacturing readiness remains unresolved.

What is the revenue exposure and market opportunity?

Nuedexta has a defensible niche because PBA is associated with chronic neurologic diseases and treatment often continues over long periods. Revenue exposure is concentrated in the branded product and its payer access rather than broad primary-care prescribing.

The largest commercial scenarios are:

• Branded lifecycle management: New dosage forms, adherence packaging, and patient-support programs.
• First generic entry: Significant price erosion with potential volume expansion.
• Second and later generic entry: Greater reimbursement pressure and reduced margins.
• Specialty generic positioning: Reliable supply, limited-launch distribution, and payer contracting.
• International expansion: Products tailored to local excipient restrictions and capsule preferences.
• Combination-product licensing: Regional rights for generic or reformulated products.

A generic entrant can compete on price, but supply reliability and regulatory readiness may be more important than incremental excipient novelty. A reformulation sponsor has greater upside if it solves a specific patient problem, such as swallowing difficulty or once-daily administration.

What geographic markets offer the best opportunity?

The United States is the most important market because of the established brand, FDA-approved indication, Orange Book framework, and mature specialty-pharmacy infrastructure. Europe and other regulated markets may offer opportunities for local fixed-dose products, but approval requirements, naming, patent status, and treatment guidelines vary by jurisdiction.

Geographic strategy should account for:

• Local approval pathway for fixed-dose combinations
• Acceptance of capsule-shell excipients
• Titanium dioxide restrictions or market-specific limitations
• Reference-product availability
• Patent term and supplementary protection
• Local pharmacovigilance requirements
• PBA diagnosis and reimbursement practices
• Manufacturing-site qualification

A global excipient strategy should avoid dependence on a single supplier or a colorant that is restricted in selected markets.

Key Takeaways

• Dextromethorphan hydrobromide and quinidine sulfate are commercialized as a 20 mg/10 mg immediate-release capsule for PBA.
• Quinidine is a CYP2D6 inhibitor that materially affects dextromethorphan exposure, making formulation equivalence clinically important.
• The core excipient strategy should prioritize content uniformity, rapid disintegration, controlled lubrication, powder flow, and moisture management.
• The lowest-risk generic product is a conventional capsule with an excipient system close to the reference product.
• Sprinkle capsules, orally disintegrating tablets, and oral suspensions are the most credible lifecycle opportunities for swallowing-impaired patients.
• There is no biosimilar pathway because both active ingredients are small molecules.
• Patent risk is concentrated in the fixed-dose combination, PBA methods of use, dose regimen, and any remaining Orange Book-listed claims.
• Excipient suppliers can compete through performance consistency, low-moisture grades, supply redundancy, and regulatory documentation.
• Generic launch timing depends on patent status, paragraph IV litigation, label carve-outs, and ANDA approval, not only on the date of original FDA approval.

FAQs

Can dextromethorphan and quinidine be formulated as a tablet instead of a capsule?

Yes. A tablet is technically feasible, but the manufacturer must match the reference product’s release and exposure characteristics. Taste masking, low-dose quinidine uniformity, and tablet disintegration are central development issues.

Is quinidine included as a second antidepressant or neurological active ingredient?

No. In this product, quinidine primarily inhibits CYP2D6 metabolism to increase dextromethorphan exposure. Its presence is pharmacokinetic rather than intended to provide the principal PBA treatment effect.

Would a gelatin-free capsule create a meaningful market advantage?

It could support vegetarian, religious, or patient-preference positioning. The commercial value is greater in selected markets than in the core U.S. generic market, where bioequivalence, price, reimbursement, and supply reliability are likely to dominate.

Can a generic manufacturer remove the capsule colorants?

Usually, a generic manufacturer can use a different appearance if it satisfies regulatory requirements and does not create confusion. The change should be evaluated for stability, product identification, patient acceptability, and regional excipient restrictions.

Is an extended-release version commercially attractive?

It could reduce dosing frequency, but it would require a more complex development program and may not qualify as a straightforward generic equivalent. The altered pharmacokinetic profile could affect both efficacy and safety.

References

1. U.S. Food and Drug Administration. (2023). Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products.
4. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly soluble, highly permeable, and rapidly dissolving drug products.
5. DailyMed. (2024). Nuedexta: Dextromethorphan hydrobromide and quinidine sulfate capsule. National Library of Medicine.
6. Otsuka Pharmaceutical Co., Ltd. (2024). Annual report and corporate information.